Maze Therapeutics (MAZE) Total Non-Current Liabilities (2024 - 2026)

Maze Therapeutics has reported Total Non-Current Liabilities for 3 years, with the latest figure at $77.6 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 95.19% year-over-year to $77.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.6 million (up 95.19% YoY) and the FY2025 annual result came in at $41.1 million, down 3.75% from the prior year.
• Total Non-Current Liabilities improved to $77.6 million in Q1 2026 per MAZE's latest filing, from $41.1 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $77.6 million in Q1 2026 and troughed at $39.8 million in Q1 2025.
• A 3-year average of $47.1 million and a median of $41.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities decreased 3.75% in 2025, then jumped 95.19% in 2026.
• Over 3 years, Total Non-Current Liabilities stood at $42.7 million in 2024, then decreased by 3.75% to $41.1 million in 2025, then soared by 89.01% to $77.6 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $77.6 million, $41.1 million, and $41.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.